Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gynecologic Cancers: early-phase trial registry
9 of 11 indexed Gynecologic Cancers trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 9 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Gynecologic Cancers: 11 US clinical trials tracked, 9 recruiting.
Gynecologic Cancers is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Atavistik Bio, running 1 of these trials.
Enrollment posture brief
Registry condition gynecologic-cancers
OPEN 9 | RECR 82% | LATE 0 | EARLY 4 | RANK #1577 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Pancreas Adenocarcinoma (82% recruiting · 11 trials)
Gynecologic Cancers lists 9 open slots (82% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gynecologic Cancers on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gynecologic Cancers is recruiting above its size-band peers.
9 of 11 indexed trials (81.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gynecologic Cancers trials is spread across many organizations.
Atavistik Bio accounts for 1 of 11 trials (9.1%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Gynecologic Cancers trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.
-
Gynecologic Cancers research is mostly interventional.
8 interventional and 3 observational studies make up this index (72.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Stanford University
NCT01034033
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
NCT07024784
Communication About Sexual Health in Gynecologic Cancer
Fox Chase Cancer Center
NCT06904339
A Prospective Study of a Lifestyle Medicine Survivorship Program for Patients With Gynecologic Cancer
AdventHealth
NCT07121738
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
Oregon State University
NCT07055854
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
John Waters
NCT07039526
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06731998
Proactive Costs of Care Study
Cedars-Sinai Medical Center
NCT07217262
Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
University of South Carolina
NCT06672497
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio
NCT07038369
Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy
University of Tennessee Graduate School of Medicine
NCT07393633
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Gynecologic Cancers records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gynecologic Cancers trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gynecologic Cancers page
11 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Gynecologic Cancers trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Atavistik Bio sponsors the most Gynecologic Cancers trials on record, review their full trial history before evaluating a specific study. See Atavistik Bio's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gynecologic Cancers condition card totals 11 registered trials; most-linked intervention ATV-1601 + Fulvestrant; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.